ArticlePloS one2025
G6PD deficiency in Malaysia's Proto-Malay Orang Asli indigenous population: A molecular and epidemiological study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is one of the most common genetic disorders worldwide and remains highly prevalent in malaria-endemic regions. Individuals with G6PDd are at risk of severe complications, including acute haemolytic anaemia, when exposed to oxidative triggers. In Malaysia, the Proto-Malay Orang Asli (PMOA), the second largest indigenous group in Peninsular Malaysia, represents a vulnerable population. This study aimed to estimate the prevalence and mutation spectrum of G6PDd in this community. A total of 258 peripheral blood samples (91 males, 167 females) were screened using a quantitative G6PD assay (OSMMR2000-D). DNA from 73 samples was genotyped with the Hybribio G6PD GenoArray test, and 39 underwent targeted sequencing. The adjusted male median (AMM) of G6PD activity was 9.6 U/gHb (95% CI: 8.9-10.3 U/gHb), with 30% and 80% thresholds corresponding to 2.9 and 7.7 U/gHb, respectively. At the 30% cut-off threshold, the overall estimated prevalence of G6PDd was 6.8% (16/237; 12 males and 4 females). A total of 21 subjects were G6PD-intermediate (7 males and 14 females), and the remaining 221 subjects were G6PD-normal (72 males and 150 females). Genotyping identified 18 hemizygous males, 13 heterozygous females, and 3 homozygous females. Five G6PD variants were detected: G6PD Viangchan (39.5%), G6PD Coimbra (28.9%), G6PD Union (23.7%), G6PD Kaiping (5.3%), and rs782038151 (2.6%). This study demonstrates that G6PDd is common in the PMOA population, with notable molecular diversity. These findings have important implications for malaria control and the safe use of antimalarial drugs in this high-risk community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.